Tirzepatide

Tirzepatide is a first-in-class prescription medication that acts as a dual agonist, simultaneously activating two naturally occurring hormone receptors in your body: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) . It's sold under two brand names: Mounjaro for treating type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea

Tirzepatide is unique because it's the first approved medication that targets two different receptors at once .

• Dual Action: It mimics two natural hormones: GIP and GLP-1. Both are incretin hormones that your body releases after eating to help regulate blood sugar .

• Blood Sugar Control: By activating these receptors, tirzepatide stimulates your pancreas to release more insulin when your blood sugar is high. It also reduces the release of glucagon, another hormone that raises blood sugar .

• Appetite and Weight: Tirzepatide acts on your brain to reduce appetite and make you feel fuller for longer. It also slows down how quickly food leaves your stomach . This combination leads to reduced food intake and significant weight loss.

• Long-Lasting Effect: The medication is designed with a C20 fatty diacid moiety that allows it to bind to albumin in your blood, giving it a long half-life of about 5 days and enabling once-weekly dosing

Tirzepatide has been studied extensively in large clinical trials and has shown impressive results.

• For Type 2 Diabetes (Mounjaro): Approved by the FDA in May 2022 as an addition to diet and exercise to improve blood sugar control in adults . In clinical trials, it proved superior to selective GLP-1 agonists like semaglutide in reducing HbA1c levels .

• For Chronic Weight Management (Zepbound): Approved by the FDA in November 2023 for adults with obesity (BMI ≥ 30 kg/m²) or those who are overweight (BMI ≥ 27 kg/m²) with at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol . In the SURMOUNT-1 trial, people taking the highest dose (15 mg) lost an average of 48 pounds (about 21% of their body weight) over 72 weeks .

• For Obstructive Sleep Apnea (Zepbound): In December 2024, the FDA approved Zepbound as the first prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity . Clinical trials showed significant reductions in breathing interruptions during sleep